IMS Health

Ims Health Inc.
Public
Traded as NYSE: Q
Industry Healthcare,
Information Services, Technology
Founded 1954 as Intercontinental Marketing Services
Headquarters Danbury, Connecticut
Key people
Ari Bousbib, CEO
Products Healthcare Measurement, Analytics & Services, Consulting, Technology Services
Revenue $2.64B[1]
Owner TPG Capital
CPP Investment Board
Leonard Green & Partners
Number of employees
14,000+[1]
Website www.imshealth.com

IMS Health is an American company that provides information, services and technology for the healthcare industry. It is the largest vendor of U.S. physician prescribing data.[2][3][4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners.[5] The company went public on April 4, 2014 and began trading on the NYSE under the symbol IMS.[1][6] Ari Bousbib is IMS Health’s Chairman and CEO. Bousbib, formerly a longtime senior executive at United Technologies Corporation,[7] joined the company in September 2010.[8] IMS Health is headquartered in Danbury, Connecticut.

Business model

IMS Health is best known for its collection of healthcare information spanning sales, de-identified prescription data, medical claims, electronic medical records[9] and social media.[10] IMS Health’s products and services are used by companies to develop commercialization plans[11] and portfolio strategies,[12] to select patient and physician populations for specific therapies, and to measure the effectiveness of pharmaceutical marketing and sales resources.[13] The firm uses its own data to produce syndicated reports such as market forecasts and market intelligence.

History and acquisitions

The original name of the company was Intercontinental Marketing Statistics, hence the IMS name. IMS Health's corporate headquarters is located in Danbury, Connecticut, United States. The company's chairman and CEO is Ari Bousbib.

Controversy

Throughout its history, IMS Health's business of collecting anonymized pharmaceutical sales data has come under scrutiny from both the media and the legal system.[27]

IMS Health v. Ayotte was a free speech case involving IMS Health.[28][29][30]

Sorrell v. IMS Health Inc. was a case about physician-data privacy, which went to the U.S. Supreme Court., the High Court ruled in favor of the company.[31][32][33][34]

References

  1. 1 2 3 IMS Health Annual Report (10-K), 2014
  2. Steinbrook, R (Jun 29, 2006). "For sale: physicians' prescribing data.". The New England Journal of Medicine. 354 (26): 2745–7. doi:10.1056/nejmp068125. PMID 16807410.
  3. Fugh-Berman, A (August 2008). "Prescription tracking and public health.". Journal of general internal medicine. 23 (8): 1277–80. doi:10.1007/s11606-008-0630-0. PMID 18473146.
  4. Fugh-Berman, A; Ahari, S (April 2007). "Following the script: how drug reps make friends and influence doctors.". PLOS Medicine. 4 (4): e150. doi:10.1371/journal.pmed.0040150. PMC 1876413Freely accessible. PMID 17455991.
  5. "IMS Health sold to TPG, CPPIB, LG&P"
  6. Picker, Leslie (2014-04-04). "TPG-Backed IMS Health Gains After $1.3 Billion Share Sale". BloombergBusiness.
  7. "CEO's of Tomorrow"
  8. http://www.businessweek.com/magazine/content/10_36/b4193016891032.htm
  9. "What Does IMS Health Do, Anyway?". The Wall Street Journal. 5 November 2009.
  10. Munro, Dan. "New Study Ranks Johnson & Johnson #1 In Pharma For Social Media Engagement". Forbes.
  11. Drive to Develop New Commercial Models.pdf "The Drive to Develop New Commercial Models"
  12. in the News/Documents/Kleinrock, 2011 CA Biomed Industry Report_FINAL.pdf "CA Biomed Industry Report"
  13. Market Maps TL.pdf "Patient Market Maps"
  14. "The Business Week 50" Bloomberg Business Week, Accessed 20 October 2010
  15. "TPG and Pension Plan to Buy IMS Health" New York Times Deal Book, 5 November 2009
  16. "IMS Health to buy clinical trials software company DecisionView"
  17. "IMS Health Acquires TTC, Strengthening Pharma R&D Services Capabilities"
  18. "IMS Health Expands Suite of Syndicated, Web-based Analytics With Acquisition of PharmaDeals Ltd."
  19. http://www.cegedim.com/communique/Cegedim_IMS_Transaction-Closing_01-04-2015_ENG.pdf
  20. fr:Cegedim
  21. Reuters (3 May 2016). "Quintiles is merging with IMS in a deal worth about $9 billion - Fortune". Fortune.
  22. "Quintiles, IMS Health to merge in $9 bln deal". Mail Online. 3 May 2016.
  23. "Quintiles, IMS Health Plan $9B Merger". GEN.
  24. Kristen Hallam; Zachary Tracer (3 May 2016). "IMS Health to Buy Quintiles in $9 Billion Pharma Data Deal". Bloomberg.com.
  25. Erik Holm. "Deals of the Day: IMS Health Merges With Quintiles, Biogen to Spin Off Hemophilia Arm". WSJ.
  26. Reuters Editorial (3 May 2016). "BRIEF-IMS Health and Quintiles to merge". Reuters.
  27. Forbes "Company that Knows What Drugs Everyone Takes Going Public" http://www.forbes.com/sites/adamtanner/2014/01/06/company-that-knows-what-drugs-everyone-takes-going-public/
  28. Baxter, Alexander D. "IMS Health v. Ayotte: A New Direction on Commercial Speech Cases" (PDF). Berkeley Technology Law Journal. 25 (1): 649–670. Retrieved 5 February 2014.
  29. Shapiro, Ilya (28 April 2009). "IMS Health v. Ayotte | Cato Institute". cato.org. Cato Institute. Retrieved 5 February 2014.
  30. Bibet-Kalinyak, Isabelle (2012). "Critical Analysis of Sorrell v. IMS Health, Inc.: Pandora's Box at Best". Food & Drug L.J. 67: 191.
  31. "IMS Health Wins Court Attack on Vermont Marketing Law". Bloomberg. 23 November 2010.
  32. Law360 11 August, 2011. Inside Sorrell V. IMS Health
  33. Adam Liptak for the New York Times. 23 June 2011 Drug Makers Win Two Supreme Court Decisions
  34. Gayland Hethcoat Regulating Pharmaceutical Marketing After Sorrell v. IMS Health Inc. Quinnipiac Health Law Journal. 2012 Vol. 15:187

External links

This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.